- Home
- PTGX vs OBDC Comparison
PTGX vs OBDC Comparison
Compare PTGX & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTGX | OBDC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.3B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PTGX | OBDC |
|---|---|---|
| Price | $105.55 | $11.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $108.23 | $14.00 |
| AVG Volume (30 Days) | 713.3K | ★ 5.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 12.81% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.24 |
| Revenue | N/A | N/A |
| Revenue This Year | $873.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.51 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.29 | $10.52 |
| 52 Week High | $107.84 | $15.19 |
Technical Indicators
Market Signals| Indicator | PTGX | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 62.52 |
| Support Level | $76.63 | $11.65 |
| Resistance Level | $107.84 | $12.10 |
| Average True Range (ATR) | 4.03 | 0.31 |
| MACD | -0.12 | 0.13 |
| Stochastic Oscillator | 84.57 | 91.54 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.